Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: Preliminary clinical experience

Renzo Colombo, A. Salonia, L. F. Da Pozzo, R. Naspro, M. Freschi, R. Paroni, M. Pavone-Macaluso, P. Rigatti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive anti-tumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have allowed the development of a system specifically designed for delivering an endovesical thermo-chemotherapy regimen in humans. In preliminary clinical experiences, insofar mainly carried out as mono-institutional investigations, the combined treatment using this system was demonstrated to be feasible, minimally invasive and safe when performed on out-patient basis. Moreover, the anti-tumoral efficacy seemed to be significantly enhanced when compared with that obtained using intravesical chemotherapy alone for both adjuvant (prophylaxis) and neo-adjuvant (ablative) approaches to superficial bladder cancer.

Original languageEnglish
Pages (from-to)127-139
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume47
Issue number2
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Combination Drug Therapy
Urinary Bladder Neoplasms
Induced Hyperthermia
Fever
Drug Therapy
Transitional Cell Carcinoma
Cytostatic Agents
Neoplasms
Urinary Bladder
Outpatients
Therapeutics
Radiation
Technology

Keywords

  • Bladder cancer
  • Chemotherapy
  • Local hyperthermia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer : Preliminary clinical experience. / Colombo, Renzo; Salonia, A.; Da Pozzo, L. F.; Naspro, R.; Freschi, M.; Paroni, R.; Pavone-Macaluso, M.; Rigatti, P.

In: Critical Reviews in Oncology/Hematology, Vol. 47, No. 2, 01.08.2003, p. 127-139.

Research output: Contribution to journalArticle

Colombo, Renzo ; Salonia, A. ; Da Pozzo, L. F. ; Naspro, R. ; Freschi, M. ; Paroni, R. ; Pavone-Macaluso, M. ; Rigatti, P. / Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer : Preliminary clinical experience. In: Critical Reviews in Oncology/Hematology. 2003 ; Vol. 47, No. 2. pp. 127-139.
@article{1c3ea5673d864127a0b6d808f7153451,
title = "Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: Preliminary clinical experience",
abstract = "The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive anti-tumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have allowed the development of a system specifically designed for delivering an endovesical thermo-chemotherapy regimen in humans. In preliminary clinical experiences, insofar mainly carried out as mono-institutional investigations, the combined treatment using this system was demonstrated to be feasible, minimally invasive and safe when performed on out-patient basis. Moreover, the anti-tumoral efficacy seemed to be significantly enhanced when compared with that obtained using intravesical chemotherapy alone for both adjuvant (prophylaxis) and neo-adjuvant (ablative) approaches to superficial bladder cancer.",
keywords = "Bladder cancer, Chemotherapy, Local hyperthermia",
author = "Renzo Colombo and A. Salonia and {Da Pozzo}, {L. F.} and R. Naspro and M. Freschi and R. Paroni and M. Pavone-Macaluso and P. Rigatti",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1040-8428(03)00076-3",
language = "English",
volume = "47",
pages = "127--139",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer

T2 - Preliminary clinical experience

AU - Colombo, Renzo

AU - Salonia, A.

AU - Da Pozzo, L. F.

AU - Naspro, R.

AU - Freschi, M.

AU - Paroni, R.

AU - Pavone-Macaluso, M.

AU - Rigatti, P.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive anti-tumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have allowed the development of a system specifically designed for delivering an endovesical thermo-chemotherapy regimen in humans. In preliminary clinical experiences, insofar mainly carried out as mono-institutional investigations, the combined treatment using this system was demonstrated to be feasible, minimally invasive and safe when performed on out-patient basis. Moreover, the anti-tumoral efficacy seemed to be significantly enhanced when compared with that obtained using intravesical chemotherapy alone for both adjuvant (prophylaxis) and neo-adjuvant (ablative) approaches to superficial bladder cancer.

AB - The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive anti-tumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have allowed the development of a system specifically designed for delivering an endovesical thermo-chemotherapy regimen in humans. In preliminary clinical experiences, insofar mainly carried out as mono-institutional investigations, the combined treatment using this system was demonstrated to be feasible, minimally invasive and safe when performed on out-patient basis. Moreover, the anti-tumoral efficacy seemed to be significantly enhanced when compared with that obtained using intravesical chemotherapy alone for both adjuvant (prophylaxis) and neo-adjuvant (ablative) approaches to superficial bladder cancer.

KW - Bladder cancer

KW - Chemotherapy

KW - Local hyperthermia

UR - http://www.scopus.com/inward/record.url?scp=0041666597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041666597&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00076-3

DO - 10.1016/S1040-8428(03)00076-3

M3 - Article

C2 - 12900006

AN - SCOPUS:0041666597

VL - 47

SP - 127

EP - 139

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -